Abstract
ANBL1531 is a COG multiarm umbrella-type phase III clinical trial in children with newly diagnosed high-risk neuroblastoma. ANBL1531 is designed to simultaneously address multiple scientific questions about the benefits of adding 131I-metaiodobenzylguanidine (MIBG) or a targeted inhibitor of signaling via the anaplastic lymphoma kinase (ALK) pathway to improve outcomes. ANBL1531 has five treatment arms. Two arms are nonrandom treatment assignments for patients who either have ALK-aberrant or MIBG non-avid disease. This chapter focuses on the remaining three arms, which are randomized treatment assignments for patients with MIBG-avid and ALK wild-type disease.
| Original language | English (US) |
|---|---|
| Title of host publication | Case Studies in Innovative Clinical Trials |
| Publisher | CRC Press |
| Pages | 19-27 |
| Number of pages | 9 |
| ISBN (Electronic) | 9781000987218 |
| ISBN (Print) | 9781032262659 |
| DOIs | |
| State | Published - Jan 1 2023 |
Bibliographical note
Publisher Copyright:© 2024 selection and editorial matter, Kristine Broglio and Binbing Yu.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'ANBL1531: The Children’s Oncology Group (COG) Experience Using a Bayesian Approach'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS